This article is more than 5 years old. Information may no longer be current.
Tumor factors predicted response to hypofractionated therapy after breast conservation
Tumor molecular subtype predicted local recurrence in women who underwent breast-conserving surgery for node-negative breast cancer, according to results of the randomized, controlled Hypofractionation Whole Breast Irradiation Trial.
Researchers set out to determine if hypoxia, molecular subtype and tumor grade predicted response to hypofractionated or standard radiotherapy after breast-conserving surgery. The analysis included 989 patients with node-negative breast cancer.
Median follow-up was 12 years. At that time, molecular subtype was the only predictive factor for local recurrence. The 10-year cumulative incidence was 16.9% for HER-2 tumors, 7.9% for luminal B tumors and 4.5% for luminal A tumors (P<.01).
“Tumor grade, molecular subtype and hypoxia did not predict response to hypofractionation, suggesting that patients with node-negative breast tumors of all grades and molecular subtypes may be safely treated with hypofractionated radiotherapy regimens,” the researchers concluded.
Disclosure: The researchers report no relevant financial disclosures.